These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 26784235)

  • 1. Molecular Pathology and Personalized Medicine: The Dawn of a New Era in Companion Diagnostics-Practical Considerations about Companion Diagnostics for Non-Small-Cell-Lung-Cancer.
    Plönes T; Engel-Riedel W; Stoelben E; Limmroth C; Schildgen O; Schildgen V
    J Pers Med; 2016 Jan; 6(1):. PubMed ID: 26784235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Quantitative Assessment of Factors Affecting the Technological Development and Adoption of Companion Diagnostics.
    Luo D; Smith JA; Meadows NA; Schuh A; Manescu KE; Bure K; Davies B; Horne R; Kope M; DiGiusto DL; Brindley DA
    Front Genet; 2015; 6():357. PubMed ID: 26858745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perspective for the development of companion diagnostics and regulatory landscape to encourage personalized medicine in Japan.
    Tazawa Y
    Breast Cancer; 2016 Jan; 23(1):19-23. PubMed ID: 25605056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Companion diagnostics-a tool to improve pharmacotherapy.
    Jørgensen JT; Hersom M
    Ann Transl Med; 2016 Dec; 4(24):482. PubMed ID: 28149844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Companion diagnostics in the era of personalized medicine--chairmen's introductory remarks].
    Fukutsuka K; Takubo T
    Rinsho Byori; 2014 Apr; 62(4):378-80. PubMed ID: 25022067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Companion diagnostics with FISH assay (HER2, ALK)].
    Hiraoka M
    Rinsho Byori; 2014 Apr; 62(4):390-8. PubMed ID: 25022069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.
    Dietel M; Jöhrens K; Laffert MV; Hummel M; Bläker H; Pfitzner BM; Lehmann A; Denkert C; Darb-Esfahani S; Lenze D; Heppner FL; Koch A; Sers C; Klauschen F; Anagnostopoulos I
    Cancer Gene Ther; 2015 Sep; 22(9):417-30. PubMed ID: 26358176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Companion diagnostics: a regulatory perspective from the last 5 years of molecular companion diagnostic approvals.
    Roscoe DM; Hu YF; Philip R
    Expert Rev Mol Diagn; 2015; 15(7):869-80. PubMed ID: 26109316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Models of partnership between the pharmaceutical and diagnostics industries around companion diagnostics for cancer and beyond.
    Ensinger C
    Expert Opin Med Diagn; 2011 Mar; 5(2):91-4. PubMed ID: 23480583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new generation of companion diagnostics: cobas BRAF, KRAS and EGFR mutation detection tests.
    Angulo B; Lopez-Rios F; Gonzalez D
    Expert Rev Mol Diagn; 2014 Jun; 14(5):517-24. PubMed ID: 24844134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Companion diagnostics for targeted cancer drugs - clinical and regulatory aspects.
    Olsen D; Jørgensen JT
    Front Oncol; 2014; 4():105. PubMed ID: 24904822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Companion diagnostic testing for targeted cancer therapies: an overview.
    Fan YS
    Genet Test Mol Biomarkers; 2013 Jul; 17(7):515-23. PubMed ID: 23574530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS mutation testing in colorectal cancer as an example of the pathologist's role in personalized targeted therapy: a practical approach.
    Domagała P; Hybiak J; Sulżyc-Bielicka V; Cybulski C; Ryś J; Domagała W
    Pol J Pathol; 2012 Nov; 63(3):145-64. PubMed ID: 23161231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of companion diagnostic device measurement performance on clinical validation of personalized medicine.
    Li M; Yu T; Hu YF
    Stat Med; 2015 Jun; 34(14):2222-34. PubMed ID: 25779099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The current landscape of the FDA approved companion diagnostics.
    Jørgensen JT
    Transl Oncol; 2021 Jun; 14(6):101063. PubMed ID: 33714919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [National variation in molecular diagnostics in metastatic lung cancer].
    Kuijpers CCHJ; van den Heuvel MM; Overbeek LIH; van Slooten HJ; van Lindert ASR; Damhuis RAM; Willems SM
    Ned Tijdschr Geneeskd; 2018 Dec; 162():. PubMed ID: 30570921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Trends in Personalized Medicine and Companion Diagnostics: A Summary From the DIA Meeting on Personalized Medicine and Companion Diagnostics.
    Tsourounis M; Stuart J; Pignato W; Toscani M; Barone J
    Ther Innov Regul Sci; 2015 Jul; 49(4):530-543. PubMed ID: 30222427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges in the codevelopment of companion diagnostics.
    Moore MW; Babu D; Cotter PD
    Per Med; 2012 Jul; 9(5):485-496. PubMed ID: 29768776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers for personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging biomedical imaging-based companion diagnostics for precision medicine.
    Liao S; Zhou M; Wang Y; Lu C; Yin B; Zhang Y; Liu H; Yin X; Song G
    iScience; 2023 Aug; 26(8):107277. PubMed ID: 37520706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.